The Real Economics of Pharma Schemes: How to Move Product Without Killing Your Margin
Anyone working in pharmaceutical sales in India knows this is a fiercely competitive business. Understanding the scheme system isn't a minor administrative detail — it is often the single factor that determines whether a distributor survives in a market where every chemist has seen every trick in the book. No experienced sales manager believes that a good product alone drives volume. What actually drives volume is a disciplined understanding of trade margins, inventory turnover, and how schemes are structured across the supply chain.
Real, sustainable revenue growth — the kind that shows up in your bank account, not just on a slide — comes from balancing stockist margins with GST compliance, without eroding your competitive advantage in the process. A well-designed volume-based discount or a retail incentive can accelerate secondary sales dramatically, which is ultimately what every P&L and ROI conversation comes back to.
This guide walks through the anatomy of pharma trade schemes across the product lifecycle — from primary sales and cash discounts to the classic "10+1" free-goods model — and explains the financial engineering that underpins how the pharma distribution channel actually runs in practice. Whether you're a first-time distributor evaluating a franchise, a stockist trying to protect eroding margins, or a sales manager designing next quarter's incentive structure, this is the operating logic you need to understand before you sign another purchase order.
If you're new to the distribution side of this business, it's worth first reading our primer on understanding the profit margins in PCD pharma franchise business before going further. If you're evaluating whether to enter pharma distribution at all, our overview on PCD pharma: a recession-proof business model is a useful starting point.
The Anatomy of a Scheme and the Reality of Margin Compression
1.1 A Scheme Is Not a Discount — It Is a Trade Strategy
In most consumer industries, demand is created by advertising directly to the end consumer. Pharma works differently. Because most purchase decisions run through a prescriber and a chemist rather than a consumer walking in and choosing a brand off a shelf, companies rely heavily on what is known as the "trade push" model. This means the incentive to sell has to be built into the channel itself — the wholesaler and the retailer need a clear commercial reason to prioritize your product over a competitor's.
This is achieved primarily through Quantity Purchase Schemes (QPS) — structured offers where a bulk purchase is rewarded with free additional stock. The most common versions are the "10+1" or "10+2" models: buy ten units, receive one or two extra units at no additional cost. Mathematically, this is close to a straight percentage discount, but functionally it behaves very differently.
When a chemist receives twelve units but is billed for only ten, the invoiced Price to Retailer (PTR) remains officially unchanged — which matters for regulatory and pricing consistency — while the two free units represent pure margin once sold. This is a deliberate strategy known as inventory loading. When a retailer's shelf and backroom space is occupied by your stock, they simply don't have the room, or the working capital, to stock a competing brand in the same category.
It's worth understanding why this psychological mechanism works so reliably in pharma retail specifically. A chemist typically operates on thin working capital and limited shelf space. Every rupee tied up in one manufacturer's stock is a rupee that cannot be spent stocking a rival brand. This is fundamentally different from FMCG retail, where shelf space is often dictated by planogram agreements and slotting fees. In pharma, the "shelf" is frequently a small counter or backroom rack, and physical occupation of that space is itself a competitive weapon. For a deeper look at how this plays out in real distribution relationships, see understanding credit management with chemists and stockists and why customer service matters in B2B pharma distribution.
1.2 The Four Building Blocks of Every Pharma Scheme
Before going further, it helps to break a scheme down into its component parts, because every scheme — no matter how it is marketed — is really a combination of these four levers:
- Free Goods (Quantity Bonus): Additional physical stock given free on a qualifying purchase (10+1, 10+2, and so on). This is the most visible and psychologically effective lever because it is tangible.
- Cash Discount: A percentage reduction tied to early payment, discussed in detail in Part 3.
- Trade Discount: A straightforward price reduction, often used defensively to match a competitor's pricing in a specific territory.
- Retail Incentive / Push Money: A reward — monetary or otherwise — paid directly to the retail counter staff or pharmacist for actively recommending a product to walk-in customers.
Most real-world schemes combine two or three of these levers simultaneously. A distributor who understands which lever is doing the actual work in a given scheme is in a much stronger position to negotiate better terms with a parent company, a topic covered in detail in tips for negotiating better rates with your pharma parent company.
1.3 Margin Compression and the "Net-Net" Reality
Statutory trade margins in India are tightly regulated, and in most cases wholesalers are capped around 8% and retailers around 16%. In a genuinely competitive market, these regulated margins are rarely enough to sustain a healthy distribution business on their own — which is precisely why the scheme structure exists as a legitimate workaround.
By layering trade discounts and free-goods offers on top of the base margin, companies effectively expand the realised margin for wholesalers to 12–15% and for retailers to 25–30%. This margin expansion is particularly important in the generic drugs segment, where brand loyalty is weak and the retailer's own incentive largely determines which product gets substituted at the counter.
The number that actually matters here is the Effective Net Price — the real, all-in cost of the product after every discount, free good, and incentive has been deducted. A distributor who tracks only the gross invoice price, without accounting for the Net-Net position, will often find gross margins evaporating even while volume appears to be growing. This is why more established operations are now using real-time data to evaluate the Contribution Margin of a scheme before it is rolled out to the field sales team, rather than reacting after the fact.
Consider a simplified illustration. A product invoiced at ₹100 per unit under a standard 8% wholesaler margin generates ₹8 of gross margin per unit. Add a 10+1 free-goods scheme, and the effective cost per unit to the wholesaler drops to roughly ₹90.90 — pushing the realised margin closer to ₹17 per unit once resold at the same market price. On paper, this looks like more than double the statutory margin. But that additional margin only materialises if the extra unit is actually sold at full value, rather than discounted further to move volume, or lost to expiry. This is exactly the gap that separates distributors who grow sustainably from those who chase volume and quietly lose money. For a broader financial framework, our guide on 7 tips for managing cash flow in a wholesale pharma business is a useful companion read, alongside best accounting software for pharma stockists for the tools needed to actually track this in practice.
1.4 Primary Sales vs. Secondary Sales: The Distinction That Makes or Breaks a Business
Understanding the difference between primary sales (sales from manufacturer to distributor) and secondary sales (sales from distributor to the retail chemist) is fundamental. Confusing the two is one of the most common reasons new distributors run into cash flow trouble.
Primary sales schemes are largely about liquidity management — clearing manufacturer inventory to hit monthly or quarterly targets. However, if that primary stock is not moving out as secondary sales at a reasonable pace, the business is effectively engaging in "channel stuffing." Left unmanaged, this results in bloated inventory days, cash tied up in unsold stock, and eventually forced stock dumping or returns.
To keep the chain moving, secondary schemes are used — funded by the manufacturer but executed by the distributor at the retail level. These are frequently structured as "value-based" schemes, rewarding the chemist across the full basket of products sold rather than a single SKU. This approach maintains healthier market hygiene and helps avoid the localized price wars that occur when one retailer receives a disproportionately large discount and begins undercutting neighbouring outlets.
A useful discipline here is to track the primary-to-secondary ratio on a rolling monthly basis. If primary purchases consistently outpace secondary sell-through by a wide margin over two or three consecutive months, that is an early warning sign — not a growth signal — regardless of how healthy the top-line invoice numbers look. Distributors who build this habit early tend to avoid the sudden, painful inventory write-downs that catch newer entrants off guard. For practical guidance on this dynamic, see managing inventory and orders in a PCD model and how to forecast demand for your pharma territory.